JSPR Class A Jasper Therapeutics, Inc. - Class A Common Stock
NASDAQ · Biotechnology · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q May 14, 2026JSPR Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
JSPR Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
| Ex-date | Split | Type |
|---|---|---|
| Jan. 4, 2024 | 1-for-10 | Reverse |
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | JSPR | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E | -0.5 | · | · | · | |
| P/B (MRQ) | 4.7 | · | 1.5 | Overvalued |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Not enough fundamentals data to compute this ratio group yet.
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | JSPR | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 2.3 | · | 2.8 | Below avg |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Not enough fundamentals data to compute this ratio group yet.
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 14, 2026 | $-0.10 | $-0.36 | 72.2% |
| March 31, 2026 | May 14, 2026 | $-0.04 | $-0.50 | 91.9% |
| Dec. 31, 2025 | $-0.32 | $-0.76 | 57.9% | |
| Sept. 30, 2025 | $-1.25 | $-1.24 | -0.87% | |
| June 30, 2025 | $-1.74 | $-1.35 | -28.6% | |
| March 31, 2025 | $-1.41 | $-1.34 | -5.3% | |
| Dec. 31, 2024 | $-1.62 | $-1.25 | -29.1% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Balance Sheet
| Metric | Trend | 2025 |
|---|---|---|
| Cash & Equivalents | $29M | |
| Prepaid Expense | $6M | |
| Other Current Assets | $664.0K | |
| Current Assets | $35M | |
| PP&E (Net) | $102.0K | |
| PP&E (Gross) | $5M | |
| Accum. Depreciation | $5M | |
| Other Non-current Assets | $113.0K | |
| Total Assets | $36M | |
| Accounts Payable | $6M | |
| Current Liabilities | $13M | |
| Other Non-current Liabilities | $2M | |
| Total Liabilities | $32M | |
| Common Stock | $3.0K | |
| Paid-in Capital | $321M | |
| Retained Earnings | $-317M | |
| Stockholders' Equity | $4M | |
| Liabilities + Equity | $36M | |
| Shares Outstanding | 27,996,819 |
Per Share
| Metric | Trend | 2025 |
|---|---|---|
| EPS (TTM) | $-3.95 |
Valuation (TTM)
| Metric | Trend | 2025 |
|---|---|---|
| Revenue TTM | $-119.0K | |
| Net Income TTM | $-76M | |
| P/E | -0.5 | |
| Earnings Yield | -215.9% |
Income Statement
| Metric | Trend | Q1 2026 |
|---|---|---|
| Cost of Revenue | $4M | |
| R&D Expense | $6M | |
| SG&A Expense | $5M | |
| Operating Expenses | $11M | |
| Operating Income | $-11M | |
| Interest Income | $164.0K | |
| Other Non-op | $-26.0K | |
| Net Income | $-1M | |
| EPS (Basic) | $-0.04 | |
| EPS (Diluted) | $-0.04 | |
| Shares (Basic) | 28,671,819 | |
| Shares (Diluted) | 28,671,819 | |
| EBITDA | $-11M |
Balance Sheet
| Metric | Trend | Q1 2026 |
|---|---|---|
| Cash & Equivalents | $14M | |
| Prepaid Expense | $6M | |
| Other Current Assets | $405.0K | |
| Current Assets | $20M | |
| PP&E (Net) | $81.0K | |
| PP&E (Gross) | $5M | |
| Accum. Depreciation | $5M | |
| Other Non-current Assets | $77.0K | |
| Total Assets | $21M | |
| Accounts Payable | $2M | |
| Current Liabilities | $9M | |
| Other Non-current Liabilities | $2M | |
| Total Liabilities | $18M | |
| Common Stock | $3.0K | |
| Paid-in Capital | $321M | |
| Retained Earnings | $-318M | |
| Stockholders' Equity | $3M | |
| Liabilities + Equity | $21M | |
| Shares Outstanding | 27,996,819 |
Cash Flow
| Metric | Trend | Q1 2026 |
|---|---|---|
| D&A | $21.0K | |
| Stock-based Comp | $423.0K | |
| Operating Cash Flow | $-15M | |
| Stock Issued | $6M | |
| Net Stock Activity | $6M |
Profitability
| Metric | Trend | Q1 2026 |
|---|---|---|
| ROA | -3.0% | |
| ROE | -5.1% |
Liquidity & Solvency
| Metric | Trend | Q1 2026 |
|---|---|---|
| Current Ratio | 2.3 | |
| Quick Ratio | 1.6 |
Per Share
| Metric | Trend | Q1 2026 |
|---|---|---|
| Book Value / Share | $0.12 | |
| Cash Flow / Share | $-0.51 | |
| Cash / Share | $0.51 | |
| EPS (TTM) | $-2.58 |
Valuation (TTM)
| Metric | Trend | Q1 2026 |
|---|---|---|
| Revenue TTM | $-175.0K | |
| Net Income TTM | $-56M | |
| Market Cap | $25M | |
| P/E | -0.3 | |
| P/S | -140.1 | |
| P/B | 7.2 | |
| P / Tangible Book | 7.2 | |
| P / Cash Flow | -1.7 | |
| Earnings Yield | -294.5% |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
Not enough fundamentals data to build this statement yet.
Not enough fundamentals data to build this statement yet.
Not enough fundamentals data to build this statement yet.
Institutional owners (13F) 51 filers · $9.5M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 4 (-9 vs prior Q) | 15 (+6 vs prior Q) | 11 (-6 vs prior Q) | 15 (0 vs prior Q) | -3.6M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| VANGUARD GROUP INC | $2,427,518 | 1,326,512 | 25.57% | Shares |
| Qiming U.S. Ventures Management, LLC | $2,210,934 | 928,964 | 23.29% | Shares |
| Velan Capital Investment Management LP | $1,020,111 | 2,423,067 | 10.75% | Shares |
| ACORN CAPITAL ADVISORS, LLC | $604,027 | 1,438,159 | 6.36% | Shares |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | $569,237 | 1,352,106 | 6.00% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $493,421 | 1,172,021 | 5.20% | Shares |
| Rock Springs Capital Management LP | $463,406 | 1,100,726 | 4.88% | Shares |
| Carlyle Group Inc. | $448,866 | 1,066,189 | 4.73% | Shares |
| MILLENNIUM MANAGEMENT LLC | $204,999 | 486,933 | 2.16% | Shares |
| Lion Point Capital, LP | $195,765 | 465,000 | 2.06% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $111,086 | 263,808 | 1.17% | Shares |
| RENAISSANCE TECHNOLOGIES LLC | $100,156 | 237,900 | 1.06% | Shares |
| CITADEL ADVISORS LLC | $86,726 | 206,000 | 0.91% | Call option |
| BlackRock, Inc. | $71,413 | 169,627 | 0.75% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $63,126 | 149,943 | 0.66% | Shares |
| ADAR1 Capital Management, LLC | $58,940 | 140,000 | 0.62% | Shares |
| Quarry LP | $55,374 | 131,529 | 0.58% | Shares |
| JANE STREET GROUP, LLC | $42,834 | 101,743 | 0.45% | Shares |
| JANE STREET GROUP, LLC | $35,196 | 83,600 | 0.37% | Call option |
| UBS Group AG | $24,737 | 58,759 | 0.26% | Shares |
| Jain Global LLC | $21,549 | 51,185 | 0.23% | Shares |
| OSAIC HOLDINGS, INC. | $19,298 | 45,850 | 0.20% | Shares |
| STATE STREET CORP | $18,818 | 44,699 | 0.20% | Shares |
| NORTHERN TRUST CORP | $17,632 | 41,882 | 0.19% | Shares |
| DIKER MANAGEMENT LLC | $15,000 | 35,000 | 0.16% | Shares |
| Qube Research & Technologies Ltd | $14,197 | 33,722 | 0.15% | Shares |
| XTX Topco Ltd | $14,064 | 33,406 | 0.15% | Shares |
| SIMPLEX TRADING, LLC | $12,036 | 28,591 | 0.13% | Shares |
| Ikarian Capital, LLC | $10,144 | 24,093 | 0.11% | Shares |
| CITADEL ADVISORS LLC | $9,430 | 22,400 | 0.10% | Put option |
| GROUP ONE TRADING LLC | $8,391 | 19,930 | 0.09% | Shares |
| Rehmann Capital Advisory Group | $6,441 | 15,300 | 0.07% | Shares |
| Sequent Planning LLC | $6,273 | 14,900 | 0.07% | Shares |
| BANK OF AMERICA CORP /DE/ | $5,975 | 14,192 | 0.06% | Shares |
| IEQ CAPITAL, LLC | $5,699 | 13,538 | 0.06% | Shares |
| Engineers Gate Manager LP | $5,468 | 12,989 | 0.06% | Shares |
| LPL Financial LLC | $5,157 | 12,250 | 0.05% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $4,326 | 10,300 | 0.05% | Put option |
| Tower Research Capital LLC (TRC) | $3,930 | 9,336 | 0.04% | Shares |
| MORGAN STANLEY | $726 | 1,724 | 0.01% | Shares |
| Arax Advisory Partners | $241 | 573 | 0.00% | Shares |
| GSA CAPITAL PARTNERS LLP | $225 | 534,697 | 0.00% | Shares |
| FEDERATED HERMES, INC. | $80 | 189 | 0.00% | Shares |
| NATIONAL BANK OF CANADA /FI/ | $63 | 160 | 0.00% | Shares |
| BNP PARIBAS FINANCIAL MARKETS | $59 | 141 | 0.00% | Shares |
| SBI Securities Co., Ltd. | $27 | 64 | 0.00% | Shares |
| JONES FINANCIAL COMPANIES LLLP | $17 | 50 | 0.00% | Shares |
| JPMORGAN CHASE & CO | $4 | 9 | 0.00% | Shares |
| SG Americas Securities, LLC | $4 | 10,556 | 0.00% | Shares |
| ROYAL BANK OF CANADA | $0 | 40 | 0.00% | Shares |
Activists & 5%+ owners 2 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Velan Capital Master Fund LP, Velan Capital Holdings LLC, Velan Horizon Fund LP, Velan Horizon GP LLC, Avego Healthcare Capital, L.P., Avego Healthcare Capital Holdings, LLC, Avego Management LLC, Velan Capital Investment Management LP, Velan Capital Management LLC, Morgan Adam, VENKATARAMAN BALAJI, Kapoor Vishal ×4 filings | July 20, 2026 | 9.88% | Amendment | M&A / sale | SEC |
| Abingworth LLP, Abingworth Bioventures VII, LP | Oct. 4, 2021 | · | Initial filing | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 22 insiders · 6 officers · 13 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Jeetinder Singh Mahal | CEO and President | Feb. 6, 2026 A | 25,009 | 0 | 0 | $0 |
| Ron Martell | President, CEO and Director | Jan. 2, 2026 A | 74,118 | 0 | 0 | $0 |
| Herb Cross | Chief Financial Officer | Jan. 2, 2026 A | · | 0 | 0 | $0 |
| Matthew E Ros | Chief Operating Officer | July 20, 2026 P | · | 0 | 0 | $0 |
| Edwin Jonathan Tucker | Chief Medical Officer | June 4, 2025 A | 400 | 0 | 0 | $0 |
| Kevin N. Heller | Executive Vice President, Research and Development | March 21, 2022 A | · | 0 | 0 | $0 |
| Patrick J Crutcher | Director | July 20, 2026 P | · | 0 | 0 | $0 |
| Judith Anne Shizuru | Director | Sept. 22, 2025 P | 156,901 | 0 | 0 | $0 |
| Svetlana Lucas | Director | Sept. 22, 2025 P | 20,000 | 0 | 0 | $0 |
| Thomas G Wiggans | Director | Sept. 22, 2025 P | 41,000 | 0 | 0 | $0 |
| Scott C. Brun | Director | July 3, 2025 A | · | 0 | 0 | $0 |
| Kapoor Vishal | Director | July 3, 2025 A | · | 0 | 0 | $0 |
| Chris Nolet | Director | July 3, 2025 A | 32,500 | 0 | 0 | $0 |
| Kurt Von Emster | Director | July 3, 2025 A | 21,175 | 0 | 0 | $0 |
| Anna Louise French | Director | June 6, 2024 A | 23,750 | 0 | 0 | $0 |
| William Lis | Director | Oct. 13, 2023 S | 53,521 | 0 | 0 | $0 |
| Lawrence Otto Klein | Director | June 7, 2023 A | 24,500 | 0 | 0 | $0 |
| Abingworth LLP | 10% owner | March 21, 2022 A | · | 0 | 0 | $0 |
| Amplitude Healthcare Holdings LLC | 10% owner | Sept. 24, 2021 M | 2,300,000 | 0 | 0 | $0 |
| Kenneth F Clifford | · | Sept. 24, 2021 M | 2,300,000 | 0 | 0 | $0 |
| Howard I Hoffen | · | Sept. 24, 2021 M | 2,300,000 | 0 | 0 | $0 |
| VENKATARAMAN BALAJI | · | Sept. 24, 2021 M | 2,300,000 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 2 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
JSPR Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
12-Month Price Target
4 analysts · 2026-09-13Mean target $7.38 +1204.8%
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.